Validation of a Japanese version of RECAP questionnaire for adult patients with atopic dermatitis and parents of pediatric patients
Not Applicable
Recruiting
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-UMIN000047132
- Lead Sponsor
- ational Hospital Organization Sagamihara National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients on biologic agents or oral JAK inhibitors with a vIGA score of 0 or 1 at the time of enrollment Patients with serious complications Patients receiving oral or intravenous immunosuppressive drugs (except cyclosporine and JAK inhibitors) and steroids If the patient is considered to have difficulty in answering the questionnaire. When the principal investigator or sub-investigator judges that participation in this study is not appropriate.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation coefficient between RECAP and each score (EASI, vIGA, ADCT, POEM, IDQoL, CDLQI, DLQI, DFI, NRS)
- Secondary Outcome Measures
Name Time Method Cronbach's alpha coefficient for each RECAP score, Intraclass correlation coefficient between test and retest in patients with no change in EASI and vIGA, Means and 95% confidence intervals of RECAP total scores among subgroups divided by vIGA scores, Means and 95% confidence intervals for differences from adjacent groups divided by vIGA scores, Minimum clinically meaningful change (MCID), Correlation coefficient with TARC and SCCA2, Correlation coefficients between changes in RECAP and changes in each score, and Area under the ROC curve of RECAP and ADCT for a rise in vIGA from 0 or 1 to >2 (relapse)